GILD // Gilead Sciences Inc.

DES <GO> NASDAQ CIK 0000882095 ↗

Health Care • Biotechnology: Biological Products (No Diagnostic Substances)

$165.61 ▲ +6.41 (+4.03%)

MKT CAP: $205.35B • VOL: 8.43M

52W L $117 52W H $176

ALTMAN Z

5.87 SAFE

PIOTROSKI

8 / 9

GILD // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 69/100 [C+] (-1 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C+

RQD CONFIDENCE

68 / 100 -1D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Upper Neutral / Watch for Breakout

01 MASSIVE / SEC XBRL

Forensic Fundamentals

15 / 20

SOLID

FCF -8.2% vs NI +200% • ROIC-WACC +13.8% • Z 5.87

02 OPRA GEX + SEC 13F

Whale & Options Flow

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

15 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

16 / 20

STRONG

20 BASE - 4 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did GILD's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever GILD is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON GILD)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 93/100 Z-SCORE: +3.36σ

GILD Accounting Gap: Net Income (+220%) Outpaced OCF (-7.5%) With +-9% Working-Capital Build

CASH CONVERSION GAP

+227.5% (NI vs OCF)

RECEIVABLES / WC BLOAT

-9.0% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Gilead Sciences Inc. (GILD) exposes a +227.5% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (-7.5%). Non-cash current assets and receivables expanded -9.0% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

GILD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.45%▲ RESISTANCE BREAKOUT

2026-10-30O $170.3H $175.7L $169.0C $170.7VOL 11.43M

RES: $167.8SUP: $142.2SMA50: $150.9SMA200: $139.9

GILD // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

NEUTRAL / PAIR TRADE CONVICTION: 55/100

BEAR 0

100 BULL

Gilead Sciences Inc. (GILD) exhibits 78.8% gross margins and 21.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 21.0x enterprise multiple and 6.5% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 78.8% gross profitability converts into 34.0% operating margin and 21.0% ROIC, outpacing sector cost of capital.

ROIC: 21.0% // GM: 78.8%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +2.4% paired with 4.60% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +2.4% // FCF YLD: 4.60%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 5.87 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.

ALTMAN Z: 5.87 // F-SCORE: 8/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 24.1x trailing P/E (22.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 24.1x // EV/EBITDA: 21.0x

02. Options Skew & Event Volatility Risk

Options market prices a ±6.5% implied move with a 0.73 put/call ratio around $162.00 max pain.

IMPL MOVE: ±6.5% // P/C: 0.73

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 28.9% net margins.

NET MARGIN: 28.9% // D/E: 0.97x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 22.4x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 0.88).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 24.1x

FORWARD P/E 22.4x

EV / EBITDA 21.0x

FCF YIELD 4.60%

GROSS MARGIN 78.8%

OPERATING MARGIN 34.0%

NET MARGIN 28.9%

ROIC % 21.0%

REV GROWTH YOY +2.4%

DILUTED EPS TTM $6.86

DEBT / EQUITY 0.97x

DIVIDEND YIELD 1.95%

RSI-14 MOMENTUM 74.3

5Y EQUITY BETA 0.88

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // GILDPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $151.54

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for GILD & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

GILD VS LLY

MARGINS ROIC VALUATION

GILD VS JNJ

MARGINS ROIC VALUATION

GILD VS ABBV

MARGINS ROIC VALUATION

GILD VS UNH

MARGINS ROIC VALUATION